



Corporate Headquarters
9009 Carothers Parkway, Suite C-2
Franklin, Tennessee 37067

Investor Contacts:
Ron Scarboro
Chief Financial Officer
ronald.scarboro@medquist.com
(615) 798-4350

Tripp Sullivan:
Corporate Communications, Inc.
tripp.sullivan@cci-ir.com
(615) 324-7335

Media Contact:
Thomas Mitchell
Director of Marketing
tmitchell@medquist.com
(615) 798-6630

MedQuist Acquires Poiesis Informatics for Next-Generation Radiology Reporting, Business Intelligence

Franklin, TN, November, 23, 2011 – MedQuist Holdings Inc. (NASDAQ: MEDH), a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, announced the acquisition of Poiesis Informatics, Inc., winner of *Aunt Minnie's Best New Radiology Company award for 2011*. The combination of Poiesis and M*Modal technologies will build on MedQuist's experience in the imaging market and bring deep analytics and business intelligence capabilities to radiology practices, expanding their insight and depth of the patient story.

Poiesis Informatics was founded in 2007 with the goal of optimizing the radiology workflow experience to allow users to be more efficient, more accurate and add measurable and differentiable value to patients. This is accomplished through Poiesis' Workflow Orchestration Suite (WOS). WOS provides interoperability between disparate systems and supports complex workflow models. Three solutions are available through WOS:

- **Catalyst™** – an enterprise unified work list that provides a consolidated view into multi-site, multi-vendor environments to drive radiologist efficiency
- **Fluency™** – an advanced clinical documentation solution leveraging M*Modal's Speech Understanding™ technology
- **Scout™** – a comprehensive business analytics tool providing robust statistical measures to monitor and improve performance, quality and safety

"The integration of M*Modal technology and the Poiesis workflow suite will promote radiology clinical documentation by providing enhanced informatics solutions," said Vern Davenport, Chairman and Chief Executive Officer of MedQuist Holdings. "Our products will provide tools to improve clinical decision-making through speech and natural language understanding and give real-time access to actionable information, adding value to PACS and RIS-driven workflow. Functionality from Poiesis will also enable our ecosystem of radiology technology partners to develop and provide even more advanced capabilities for their customers."

-MORE-

November 23, 2011

“We are excited to join MedQuist,” said Claudine Martin, President of Poiesis Informatics. “We set out to transform the workflow of the radiologist. With the addition of M*Modal technology, we will accelerate that vision by providing unique and innovative solutions to the market. Our philosophy has always been that patient care is enhanced by making clinical information available to the radiologist from the EHR, ancillary systems such as lab values and pathology results.”

MedQuist and Poiesis will showcase many of these new technologies at the upcoming RSNA 2011, the 97th Scientific Assembly and Annual Meeting in Chicago, November 27 – December 2. The company will be represented in booth 7713 for providers and booth 8944 for partners.

About MedQuist Holdings

MedQuist is a leading provider of clinical narrative capture services, Speech Understanding technology from M*Modal and clinical documentation workflow. MedQuist's enterprise solutions – including mobile voice capture devices, speech recognition, Web-based workflow platforms and global network of medical editors – help healthcare facilities facilitate adoption of electronic health records (EHR), improve patient care, increase physician satisfaction and lower operational costs. For more information, please visit www.medquist.com.

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this press release regarding MedQuist's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Actual outcomes and results may differ materially from what is expressed or forecasted in forward-looking statements. As a result, forward-looking statements speak only as of the date they were made, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###